GENMAB A/S will ask shareholders to approve 2026 board remuneration centered on a DKK 600,000 annual base fee, committee fees and RSUs worth 2.5 to 3 times that fee. The proposal matters because shareholders must decide whether the unchanged compensation structure from 2024 and 2025 remains in place.
Key Highlights
- Committee fees range from DKK 70,000 to DKK 150,000 annually, with DKK 10,000 paid per committee meeting.
- Genmab will ask shareholders on October 7 to approve unchanged 2026 board remuneration, including a DKK 600,000 annual base fee for each board member.
- The proposed package includes committee fees, DKK 10,000 per committee meeting for every committee member, and restricted stock units under Genmab’s remuneration policy.
- Shareholders’ voting rights depend on holdings on September 30, 2026; attendance registration is due by October 2, 2026.
GENMAB A/S (NASDAQ: GMAB) will ask shareholders to approve remuneration for its Board of Directors for 2026, with the annual base fee set at DKK 600,000 for board members. The proposed package, covering base fees, committee payments and share-based remuneration, remains unchanged from 2024 and 2025.
October 7 Remuneration Vote
The meeting’s agenda places the 2026 board remuneration proposal first, followed by any other business. Approval requires a simple majority of votes. The board conducted Shareholder outreach after that meeting, including discussions with shareholders and proxy advisors.
Fees Set Across Committees
The annual base fee for each Board of Directors member is DKK 600,000. The board chair would receive twice that base fee, while the deputy chair would receive one and a half times the base fee. Annual committee fees vary by committee and role. The Audit and Finance Committee chair would receive DKK 150,000, with members receiving DKK 100,000. The Compensation Committee chair would receive DKK 120,000, while committee members would receive DKK 80,000. The Scientific Committee chair would receive DKK 130,000, and its members would receive DKK 100,000. Every committee member would also receive DKK 10,000 for each committee meeting.
RSUs Form Part of Package
Share-based remuneration would be delivered through restricted stock units under Genmab’s Remuneration Policy for the Board of Directors and Executive Management. The remuneration proposal therefore combines fixed payments, committee fees and equity-linked awards within the package submitted for shareholder approval. Shareholders’ participation and voting rights will be determined by holdings on September 30, 2026. Attendance registration must be completed by October 2, 2026, with electronic and written registration Options available under the meeting instructions.



Please wait processing your request...